Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.001--Not Available
Seborrhoea23.02.07.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Sexual dysfunction21.03.02.003; 19.08.05.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin atrophy23.01.05.001--
Skin disorder23.03.03.007--Not Available
Skin erosion23.07.03.0020.001250%Not Available
Skin exfoliation23.03.07.0030.009498%Not Available
Skin fissures23.03.03.008--Not Available
Skin fragility23.03.03.009--Not Available
Skin hypertrophy23.01.04.002--Not Available
Skin irritation23.03.04.009--Not Available
Skin lesion23.03.03.0100.001250%Not Available
Skin odour abnormal23.03.03.012--
Skin papilloma23.10.01.002; 16.26.01.002; 11.05.07.001--
Skin ulcer24.04.03.007; 23.07.03.0030.003999%
Somnolence19.02.05.003; 17.02.04.006--
Sputum increased22.02.03.007--Not Available
Squamous cell carcinoma16.16.01.0020.004374%Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.001250%Not Available
Stomatitis07.05.06.005--
Suicidal ideation19.12.01.0030.001250%
Sunburn23.03.09.007; 12.05.02.001--Not Available
Sweat gland disorder23.02.03.010--Not Available
Swelling08.01.03.015--Not Available
Syncope17.02.04.008; 02.11.04.015; 24.06.02.012--
Tendonitis15.07.01.003; 12.01.07.007--Not Available
Tension19.06.02.005--Not Available
Therapeutic response decreased08.06.01.0160.004874%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene